Literature DB >> 19303619

Maternal neutralizing antibodies against a CRF01_AE primary isolate are associated with a low rate of intrapartum HIV-1 transmission.

Tanawan Samleerat1, Suzie Thenin, Gonzague Jourdain, Nicole Ngo-Giang-Huong, Alain Moreau, Pranee Leechanachai, Jirapan Ithisuknanth, Karin Pagdi, Pornpun Wannarit, Suraphan Sangsawang, Marc Lallemant, Francis Barin, Martine Braibant.   

Abstract

Mother-to-child transmission (MTCT) of HIV-1 provides a model for studying the role of passively acquired antibodies in preventing HIV infection. We determined the titers of neutralizing antibodies (NAbs) against six primary isolates of clades B and CRF01_AE in sera from 45 transmitting and 45 nontransmitting mothers matched for the main independent factors associated with MTCT in Thailand. A lower risk of MTCT, particularly for intrapartum transmission, was associated only with higher NAb titers against the CRF01_AE strain, MBA. The envelope glycoprotein of this strain showed an unusually long V2 domain of 63 amino acids, encoding six potential N-linked glycosylation sites. We provided experimental data indicating that the extended V2 domain contributed to the higher level of resistance to neutralization by mothers' sera in this strain. Taken together the data suggest that some primary isolates with specific properties may be useful indicators for identifying protective antibodies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19303619      PMCID: PMC4468066          DOI: 10.1016/j.virol.2009.02.024

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  27 in total

1.  Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity.

Authors:  Martine Braibant; Sylvie Brunet; Dominique Costagliola; Christine Rouzioux; Henri Agut; Hermann Katinger; Brigitte Autran; Francis Barin
Journal:  AIDS       Date:  2006-10-03       Impact factor: 4.177

2.  Lack of autologous neutralizing antibody to human immunodeficiency virus type 1 (HIV-1) and macrophage tropism are associated with mother-to-infant transmission.

Authors:  J L Lathey; J Tsou; K Brinker; K Hsia; W A Meyer; S A Spector
Journal:  J Infect Dis       Date:  1999-08       Impact factor: 5.226

3.  A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. Perinatal HIV Prevention Trial (Thailand) Investigators.

Authors:  M Lallemant; G Jourdain; S Le Coeur; S Kim; S Koetsawang; A M Comeau; W Phoolcharoen; M Essex; K McIntosh; V Vithayasai
Journal:  N Engl J Med       Date:  2000-10-05       Impact factor: 91.245

4.  Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1.

Authors:  E J Platt; K Wehrly; S E Kuhmann; B Chesebro; D Kabat
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

Review 5.  Maternal immunization against viral disease.

Authors:  J Englund; W P Glezen; P A Piedra
Journal:  Vaccine       Date:  1998 Aug-Sep       Impact factor: 3.641

6.  Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection.

Authors:  Rong Rong; Frederic Bibollet-Ruche; Joseph Mulenga; Susan Allen; Jerry L Blackwell; Cynthia A Derdeyn
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

Review 7.  Immunoprophylaxis to prevent mother-to-child transmission of HIV-1.

Authors:  Jeffrey T Safrit; Ruth Ruprecht; Flavia Ferrantelli; Weidong Xu; Moiz Kitabwalla; Koen Van Rompay; Marta Marthas; Nancy Haigwood; John R Mascola; Katherine Luzuriaga; Samuel Adeniyi Jones; Bonnie J Mathieson; Marie-Louise Newell
Journal:  J Acquir Immune Defic Syndr       Date:  2004-02-01       Impact factor: 3.731

8.  N-Glycans in the gp120 V1/V2 domain of the HIV-1 strain NL4-3 are indispensable for viral infectivity and resistance against antibody neutralization.

Authors:  Tobias Wolk; Michael Schreiber
Journal:  Med Microbiol Immunol       Date:  2006-03-18       Impact factor: 3.402

9.  Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin.

Authors:  Ming Zhang; Brian Gaschen; Wendy Blay; Brian Foley; Nancy Haigwood; Carla Kuiken; Bette Korber
Journal:  Glycobiology       Date:  2004-06-02       Impact factor: 4.313

10.  Genetic analysis of human immunodeficiency virus type 1 envelope V3 region isolates from mothers and infants after perinatal transmission.

Authors:  N Ahmad; B M Baroudy; R C Baker; C Chappey
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

View more
  17 in total

Review 1.  Neutralizing antibodies and control of HIV: moves and countermoves.

Authors:  Ann J Hessell; Nancy L Haigwood
Journal:  Curr HIV/AIDS Rep       Date:  2012-03       Impact factor: 5.071

Review 2.  The Antibody Response against HIV-1.

Authors:  Julie Overbaugh; Lynn Morris
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

3.  The V1V2 domain and an N-linked glycosylation site in the V3 loop of the HIV-1 envelope glycoprotein modulate neutralization sensitivity to the human broadly neutralizing antibody 2G12.

Authors:  Antoine Chaillon; Martine Braibant; Thierry Moreau; Suzie Thenin; Alain Moreau; Brigitte Autran; Francis Barin
Journal:  J Virol       Date:  2011-01-19       Impact factor: 5.103

Review 4.  Immunotherapies to prevent mother-to-child transmission of HIV.

Authors:  Mark D Hicar
Journal:  Curr HIV Res       Date:  2013-03       Impact factor: 1.581

5.  Effect of Amino Acid Substitutions Within the V3 Region of HIV-1 CRF01_AE on Interaction with CCR5-Coreceptor.

Authors:  Sayamon Hongjaisee; Martine Braibant; Francis Barin; Nicole Ngo-Giang-Huong; Wasna Sirirungsi; Tanawan Samleerat
Journal:  AIDS Res Hum Retroviruses       Date:  2017-06-12       Impact factor: 2.205

6.  The breadth and titer of maternal HIV-1-specific heterologous neutralizing antibodies are not associated with a lower rate of mother-to-child transmission of HIV-1.

Authors:  Antoine Chaillon; Thierry Wack; Martine Braibant; Laurent Mandelbrot; Stéphane Blanche; Josiane Warszawski; Francis Barin
Journal:  J Virol       Date:  2012-07-18       Impact factor: 5.103

7.  The breadth and potency of passively acquired human immunodeficiency virus type 1-specific neutralizing antibodies do not correlate with the risk of infant infection.

Authors:  John B Lynch; Ruth Nduati; Catherine A Blish; Barbra A Richardson; Jennifer M Mabuka; Zahra Jalalian-Lechak; Grace John-Stewart; Julie Overbaugh
Journal:  J Virol       Date:  2011-03-16       Impact factor: 5.103

Review 8.  Antibodies for prevention of mother-to-child transmission of HIV-1.

Authors:  Genevieve G Fouda; M Anthony Moody; Sallie R Permar
Journal:  Curr Opin HIV AIDS       Date:  2015-05       Impact factor: 4.283

9.  Evidence for efficient vertical transfer of maternal HIV-1 envelope-specific neutralizing antibodies but no association of such antibodies with reduced infant infection.

Authors:  Maxwel M Omenda; Caitlin Milligan; Katherine Odem-Davis; Ruth Nduati; Barbra A Richardson; John Lynch; Grace John-Stewart; Julie Overbaugh
Journal:  J Acquir Immune Defic Syndr       Date:  2013-10-01       Impact factor: 3.731

10.  Two N-linked glycosylation sites in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 regulate viral neutralization susceptibility to the human monoclonal antibody specific for the CD4 binding domain.

Authors:  Piraporn Utachee; Shota Nakamura; Panasda Isarangkura-Na-Ayuthaya; Kenzo Tokunaga; Pathom Sawanpanyalert; Kazuyoshi Ikuta; Wattana Auwanit; Masanori Kameoka
Journal:  J Virol       Date:  2010-02-17       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.